--Agenus, an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, announced expanded data from the Company’ s Phase 1 study of botensilimab and balstilimab in patients with advanced sarcoma. The results will be presente
Agenus Inc. (NASDAQ:AGEN) Q4 2021 Earnings Conference Call March 1, 2022 8:30 AM ETCompany ParticipantsDivya Vasudevan – Senior Director, Oncology Strategy...